Head and neck cancers, particularly those involving the oral cavity, are associated with high morbidity and mortality rates globally.
Despite advancements in surgical techniques, chemotherapy, and radiotherapy, the development of second primary malignancies (SPMs) remains a critical concern for longterm survivors.
The occurrence of metachronous double primary malignancies, where the second primary cancer arises at a different anatomical site and time, poses additional diagnostic and therapeutic challenges.
